Results 61 to 70 of about 31,390 (228)

CD39: Interface Between Vascular Thrombosis and Inflammation [PDF]

Current Atherosclerosis Reports, 2014
Extracellular nucleotides play a critical role in vascular thrombosis and inflammation. Alterations in purinergic extracellular nucleotide concentrations activate pathways that result in platelet degranulation and aggregation, and endothelial and leukocyte activation and recruitment.
Yogendra M, Kanthi, Nadia R, Sutton, David J, Pinsky   +2 more
openaire   +2 more sources

CD39/CD73/A2AR pathway and cancer immunotherapy

Molecular Cancer, 2023
AbstractCancer development is closely associated with immunosuppressive tumor microenvironment (TME) that attenuates antitumor immune responses and promotes tumor cell immunologic escape. The sequential conversion of extracellular ATP into adenosine by two important cell-surface ectonucleosidases CD39 and CD73 play critical roles in reshaping an ...
Chenglai Xia, Shuanghong Yin, Kenneth K. W. To, Liwu Fu   +3 more
openaire   +3 more sources

A humanized monoclonal antibody targeting CD39 with novel mechanism for cancer treatment

Medicine in Drug Discovery, 2021
ATP-adenosine signal axis plays an import role in tumor immune regulation. ATP released by tumor cells can promote antitumor immunity, and adenosine can suppress the immune response.
Zheng Wei, Fang Ren, Shiyong Gong, Beilei Shi, Kedong Ouyang, Chengbin Wu   +5 more
doaj   +1 more source

Chronic HBV Infection Disrupts CCL5‐Secreting cNK Cells and Attenuates Liver Accumulation and Activation of DCs and HBV‐Specific T Cells

Advanced Science, EarlyView.
ADORA2A activation suppresses NFκB‐dependent CCL5 production in cNK cells during chronic HBV infection, disrupting intrahepatic DC recruitment and HBV‐specific CD8+ T‐cell differentiation and function. Targeting the ADORA2A/NFκB/CCL5 axis restores antiviral immunity and facilitates HBV clearance.
Ailu Yang, Yucan Wang, Yating Yu, Jing Wu, Cuiping Bao, Zixuan Wang, Qiuju Han, Zhigang Tian, Jian Zhang, Huajun Zhao   +9 more
wiley   +1 more source

Ruolo di due ectoenzimi, CD39 e CD73, nella modulazione dei processi infiammatori nel ratto [PDF]

, 2008
La manipolazione del decorso e dell'intensità di un processo infiammatorio può avvenire non solo impiegando agenti che inibiscano le "pathways proinfiammatorie" attivate, ma anche mediante un approccio volto ad attivare i processi antinfiammatori ...
CICALA, CARLA
core  

신세포암에서 종양침윤 CD39+CD8+ T세포의 특성에 대한 연구 [PDF]

, 2022
학위논문(박사) - 한국과학기술원 : 의과학대학원, 2022.2,[v, 57 p. :]Despite CD39 expression on tumor-infiltrating $CD8^+$ T cells have been mostly highlighted as a marker for exhausted cells or tumor antigen-reactive cells, CD39 is known to play a role in immuno-suppressive
Lee, Yong Joon
core  

Inosine‐Triphosphate‐Pyrophosphatase Activity as a Potential Predictor of Methotrexate Remission in Juvenile Idiopathic Arthritis

Arthritis &Rheumatology, EarlyView.
Objective Methotrexate (MTX) is the first‐line therapy for juvenile idiopathic arthritis (JIA), but up to 40% of patients do not respond to it. Low inosine triphosphate pyrophosphatase (ITPA) activity has been associated with reduced clinical remission. We investigated the role and underlying mechanisms of ITPA in vitro. Methods ITPA enzymatic activity
Sofia Sindici Forgiarini, Marianna Lucafò, Debora Curci, Davide Selvestrel, Valentina Moressa, Sofia Pagarin, Barbara Bellich, Martina Franzin, Alberto Tommasini, Mara L. Becker, Laura B. Ramsey, Susan D. Thompson, Carl D. Langefeld, Federica Corba, Edoardo Marrani, Gabriele Simonini, Gabriele Stocco, Giuliana Decorti, Andrea Taddio, Serena Pastore   +19 more
wiley   +1 more source

Interleukin‐2 Deprived State of Regulatory T cells and Their Recovery by Low‐Dose Interleukin‐2 in Patients With Inflammatory Myopathies

Arthritis &Rheumatology, EarlyView.
Objective Regeneration and expansion of Treg by low‐dose interleukin‐2 (IL‐2) therapy is considered a potential treatment strategy for a wide range of autoimmune diseases. To provide a pathophysiologically‐based rationale for low‐dose IL‐2 therapy, we investigated whether reversible defects in the Treg–IL‐2 axis emerge in inflammatory myopathies ...
Justus Ohmes, Luisa R. Monne, Sara Comdühr, Fynn Gerlach, Hanna Grasshoff, Alexander Dübbers, Antje Müller, Alexander Scheffold, Gabriela Riemekasten, Reza Akbarzadeh, Jens Y. Humrich   +10 more
wiley   +1 more source

Expression of CD39 and CD73 ectonucleotidases and associated ectoenzymatic activity. [PDF]

, 2014
(A) Mean (+SEM) frequency of (A) CD39+ cells, (B) CD39 mean fluorescence intensity (MFI) and of (C) CD39+CD73+ cells within CD4mem at baseline and within Th17, iT-reg and supTh17. Results from 12 healthy subjects are shown. *P≤0.05; **P≤0.01; ***P≤0.001.
Yan Wu (70890), Maria Serena Longhi (520577), Aiping Bai (397605), Francisco J. Quintana (153929), Simon C. Robson (301209), Alan Moss (520578), Adam Cheifetz (520579), Huang Huang (68392)   +7 more
core   +1 more source

Generation and characterization of antagonistic anti-human CD39 nanobodies

Frontiers in Immunology
CD39 is the major enzyme controlling the levels of extracellular adenosine triphosphate (ATP) via the stepwise hydrolysis of ATP to adenosine diphosphate (ADP) and adenosine monophosphate (AMP).
Stephan Menzel, Stephan Menzel, Stephan Menzel, Yinghui Duan, Julia Hambach, Birte Albrecht, Dorte Wendt-Cousin, Riekje Winzer, Eva Tolosa, Anne Rissiek, Anne Rissiek, Andreas H. Guse, Friedrich Haag, Tim Magnus, Friedrich Koch-Nolte, Björn Rissiek   +15 more
doaj   +1 more source